Ryoko Shimizu
Overview
Explore the profile of Ryoko Shimizu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
169
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fujimoto D, Kato R, Morimoto T, Shimizu R, Sato Y, Kogo M, et al.
PLoS One
. 2016 Dec;
11(12):e0168465.
PMID: 28006019
Background: Data on characteristics, outcomes, and prognosis of advanced non-small-cell lung cancer (NSCLC) patients who develop pneumonitis during systemic anti-cancer therapy (pneumonitis) are currently lacking. Methods: We conducted a retrospective...
2.
Sato Y, Fujimoto D, Uehara K, Shimizu R, Ito J, Kogo M, et al.
BMC Cancer
. 2016 Nov;
16(1):890.
PMID: 27842505
Background: This study aimed to assess the prognostic accuracy of serum CA 19-9 in patients with advanced lung adenocarcinoma. Methods: We retrospectively reviewed data of 246 patients who were diagnosed...
3.
Matsumoto T, Otsuka K, Kato R, Shimizu R, Otoshi T, Fujimoto D, et al.
Exp Ther Med
. 2015 Dec;
10(2):659-664.
PMID: 26622371
Patients frequently experience great discomfort during a bronchoscopy for the diagnosis of lung neoplasms. Sedation is generally recommended during bronchoscopy; however, few studies have evaluated the discomfort and tolerability of...
4.
Fujimoto D, Shimizu R, Kato R, Sato Y, Kogo M, Ito J, et al.
Anticancer Res
. 2015 Oct;
35(11):6261-6.
PMID: 26504060
Background: The safety and efficacy of second-line chemotherapy for treating patients with small cell lung cancer (SCLC) and interstitial lung disease (ILD) have not been elucidated to date. Patients And...
5.
Kogo M, Shimizu R, Uehara K, Takahashi Y, Kokubo M, Imai Y, et al.
Lung Cancer
. 2015 Sep;
90(2):364-8.
PMID: 26384434
Objectives: Several different acquired resistance mechanisms to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy have been described. Although rare, the transformation from adenocarcinoma to small cell carcinoma (SCLC)...
6.
Fujimoto D, Shimizu R, Morimoto T, Kato R, Sato Y, Kogo M, et al.
Eur Respir J
. 2014 Oct;
45(4):1098-107.
PMID: 25323241
Data on prognosis and predictors of overall survival in advanced lung cancer patients diagnosed following emergency admission (DFEA) are currently lacking. We retrospectively analysed data from 771 patients with advanced...
7.
Shimizu R, Fujimoto D, Kato R, Otoshi T, Kawamura T, Tamai K, et al.
Cancer Chemother Pharmacol
. 2014 Sep;
74(6):1159-66.
PMID: 25245821
Purpose: Optimal chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD) is established for paclitaxel and carboplatin, but is otherwise controversial. Therefore, we assessed...
8.
Fujimoto D, Ueda H, Shimizu R, Kato R, Otoshi T, Kawamura T, et al.
Clin Exp Metastasis
. 2014 Apr;
31(5):543-51.
PMID: 24682604
Mutated epidermal growth factor receptor (EGFR) and signaling pathways were associated with multiple brain and intra-pulmonary metastases, oncogenic progression and metastasis. However, features of metastasis to other organs and the...
9.
Kim Y, Shimizu R, Nakai H, Mori H, Okuyama M, Kang M, et al.
Appl Microbiol Biotechnol
. 2011 Apr;
91(2):329-39.
PMID: 21479716
Multiple forms of native and recombinant endo-dextranases (Dexs) of the glycoside hydrolase family (GH) 66 exist. The GH 66 Dex gene from Streptococcus mutans ATCC 25175 (SmDex) was expressed in...
10.
Nakano T, Katafuchi A, Shimizu R, Terato H, Suzuki T, Tauchi H, et al.
Nucleic Acids Res
. 2005 Apr;
33(7):2181-91.
PMID: 15831791
Nitric oxide (NO) induces deamination of guanine, yielding xanthine and oxanine (Oxa). Furthermore, Oxa reacts with polyamines and DNA binding proteins to form cross-link adducts. Thus, it is of interest...